Results 111 to 120 of about 62,685 (235)

TRIM59 Drives Bladder Cancer Progression Through E3 Ligase‐Dependent K48‐Linked Degradation of PTRF

open access: yesCancer Science, EarlyView.
Schematic model of TRIM59‐driven BLCA progression through K48‐linked ubiquitination and proteasomal degradation of PTRF, leading to AKT activation and c‐Myc upregulation. ABSTRACT Tripartite motif‐containing 59 (TRIM59) is an E3 ubiquitin ligase implicated in multiple malignancies, but its role in bladder cancer (BLCA) remains incompletely understood ...
Junlin Gan   +9 more
wiley   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

open access: yesCancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu   +8 more
wiley   +1 more source

Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer

open access: yesCancer Science, EarlyView.
Integrated analysis of 445 bladder cancers showed that HER2 membrane expression and ERBB2 amplification are distinct features. HER2 expression overlapped with NECTIN4 expression, whereas ERBB2 amplification was enriched in the LumU subtype and associated with poor prognosis.
Kensuke Hirosuna   +13 more
wiley   +1 more source

Liquid Biopsy and Multi‐Cancer Early Detection Tests for Cancer Screening: A Scoping Review

open access: yesClinical Genetics, EarlyView.
There is a large body of evidence on liquid biopsy and multi‐cancer detection tests for cancer screening. Most studies addressed test performance outcomes, while fewer addressed clinical outcomes, implementation, and cost‐effectiveness. No studies evaluated cancer mortality.
Tessa Robinson   +6 more
wiley   +1 more source

When Small Cells Matter: Diagnosing Bladder Small Cell Carcinoma on Urine Cytology

open access: yesCytopathology, EarlyView.
Small cell carcinoma of the bladder is rare, aggressive and diagnostically challenging on urine cytology. We report a case detected in urine and confirmed by cell block immunohistochemistry, highlighting the importance of careful assessment and limitations of the Paris System.
Haley Corbin   +3 more
wiley   +1 more source

NFE2L2‐mutated urothelial carcinomas frequently show concomitant myxoid and squamous features and have high PD‐L1 expression

open access: yesHistopathology, EarlyView.
Aims NFE2L2 encodes the transcription factor, NRF2, which is a regulator of cellular oxidative stress responses and metabolic homeostasis. NFE2L2 alterations are implicated in multiple cancers, with significant study in thoracic oncology, with an adverse prognosis, aggressive behaviour, metabolic reprogramming and diminished responses to chemotherapy ...
Dane Wuori   +5 more
wiley   +1 more source

Urothelial Carcinoma in a Cat with Bilateral Ectopic Ureters. [PDF]

open access: yesAnimals (Basel)
Piazza C   +7 more
europepmc   +1 more source

Merkel cell carcinoma: an updated guide for pathologists

open access: yesHistopathology, EarlyView.
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma for which the differential diagnosis can include other small cell malignancies (especially metastatic small cell carcinoma) or cutaneous carcinoma. Morphologic and immunophenotypic aberrancies in MCC can increase diagnostic challenge.
Paul W. Harms
wiley   +1 more source

Home - About - Disclaimer - Privacy